AzTrials
AzTrials

Tachycardia, VentricularRASA-VTNCT03779165

R Wave Sensing After VT Ablation

An observational study of Tachycardia, Ventricular and Catheter Ablation, run by University Hospital Sestre Milosrdnice at 4 sites in 2 countries.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Sustained, monomorphic ventricular tachycardia (VT) is most commonly encountered in patients with structural heart disease, usually with ischemic aetiology. It has been proven that repeated episodes of sustained VT contribute to the mortality of patients with structural heart disease. Read more about this study

Who is it for?
Ages 18 years and older
How many people
100 participants
Where
4 sitesin 2 countries
Study dates
Dec 2018to Dec 2020
How long will I take part?
12 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with structural heart disease (ischemic and non-ischemic aetiology) implanted with implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy cardioverter defibrillator (CRT-D) and recurrent, sustained, monomorphic ventricular tachycardia, who are, according to their cardiologist, planned for 3D mapping and radiofrequency ablation of ventricular tachycardia myocardial substrate.

Who may be able to join

  • patients with recurrent, sustained ventricular tachycardia
  • patients implanted with implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy cardioverter defibrillator (CRT-D)
  • patients planned for 3D mapping and radiofrequency ablation of ventricular tachycardia myocardial substrate
  • patients who are able to understand and sign informed consent

Who cannot join

  • Patients with combined mechanical aortic and mitral valve prostheses
  • Patients with RF ablation of VT done in the last 12 months
  • Patients with known damaged ICD/CRT-D electrode or battery
  • Patients undergoing VT ablation who have not been implanted with ICD or CRT-D
  • Patients not willing or able to undergo clinical follow-up of ICD/CRT-D device
  • Patients with life expectancy < 1 year
  • Not able to understand or willing to sign informed consent
  • Age < 18 years

Trial locations and contacts

4 sites in 2 countries.

Ivan Zeljkovic, MD contact

0038513787733

ivanzeljkov@gmail.com

Nikola Pavlovic, MD contact

0038513787111

nikolap12@yahoo.com

4 sites in 2 countries

Croatia2 sites
  • University Hospital Rijeka

    Rijeka, 51000

    Sandro Brusich, MD, 0038551658111, sandro.brusich@gmail.com

  • University Hospital Sestre milosrdnice

    Zagreb, 10000

    Ivan Zeljkovic, MD, 0038513787733, ivanzeljkov@gmail.com

Other trials in Croatia

Switzerland2 sites
  • University Hospital Basel

    Basel, 4031

    Christian Sticherling, MD, +41 61 265 44 44, christian.sticherling@usb.ch

  • University Hospital Bern

    Bern, 3012

Other trials in Switzerland

About this study

Official title: R Wave Sensing After Radiofrequency Ablation of Ventricular Tachycardia Substrate in Patients With Structural Heart Disease

Sustained, monomorphic ventricular tachycardia (VT) is most commonly encountered in patients with structural heart disease, usually with ischemic aetiology. It has been proven that repeated episodes of sustained VT contribute to the mortality of patients with structural heart disease. These patients are usually implanted with implantable cardioverter defibrillator without (ICD) or with cardiac resynchronisation therapy (CRT-D). According to the current guidelines 3D mapping with radiofrequency (RF) ablation of the tachycardia substrate is an established therapeutic option. As part of the clinical follow-up of patients implanted with cardiac implantable electronic devices (CIED), CIED function parameters are monitored every 6 months, which is always done before and after any procedure involving RF ablation. Furthermore, a transient drop of R wave sensing has been demonstrated after the atrioventricular (AV) node ablation in patients with single-chamber pacemakers and fast atrial fibrillation. The aim of this study is to assess the change in R wave sensing after the RF ablation of VT substrate.

This study will be performed as a clinical, prospective, multi-centre, observational cohort study with a structured follow-up period of 12 months. All consecutive patients with sustained VT implanted with ICD or CRT-D undergoing RF ablation procedure of myocardial substrate, who are able to understand and sign informed consent, will be enrolled. Primary objective is a R wave sensing drop > 30% after VT substrate ablation procedure. Recruiting should not exceed 12 months with the minimal follow-up period of 12 months (24 months in total). Standardized statistical methods and test will be done using SPSS Software Version 22.0 or newer.

This unique study offers the possibility to show the impact of RF ablation on short-term and long-term R wave sensing change assessed by ICD or CRT-D's ventricle electrode in patients with sustained VT and structural heart disease undergoing ablation procedure. This observational data is needed to further refine the treatment of these patients and to prevent possible ICD/CRT-D dysfunction which could endanger this patient population.

Read the detailed description

Sustained, monomorphic ventricular tachycardia (VT) is most commonly encountered in patients with structural heart disease, usually with ischemic aetiology. It has been proven that repeated episodes of sustained VT contribute to the mortality of patients with structural heart disease. These patients are usually implanted with implantable cardioverter defibrillator without (ICD) or with cardiac resynchronisation therapy (CRT-D) as part of sudden cardiac death (SCD) prevention and have had activation of the device due to the sustained VT episodes. According to the current guidelines 3D mapping with radiofrequency (RF) ablation of the tachycardia substrate is an established therapeutic option. As part of the clinical follow-up of patients implanted with cardiac implantable electronic devices (CIED), including ICDs and CRT-Ds, function parameters are monitored every 6 months. The same check-up is done before and after any procedure involving RF ablation. Furthermore, a transient drop of R wave sensing has been demonstrated after the RF ablation of the atrioventricular (AV) node in patients with uncontrollable fast atrial fibrillation implanted with single-chamber pacemakers. The above mentioned have not been studied yet in patients ablated due to sustained VT. Hence, the aim of this study is to assess the change in R wave sensing after the RF ablation of VT substrate in patients with structural heart disease.

This study will be performed as a clinical, prospective, multi-centre, observational (analytic, longitudinal) cohort study with patient enrolment in 4 electrophysiology centres in Croatia and Switzerland and a structured follow-up period of 12 months.

All consecutive patients with sustained VT implanted with ICD or CRT-D undergoing RF ablation procedure of myocardial substrate, who are able to understand and sign informed consent, will be enrolled.

Exclusion criteria:

  • Patients with combined mechanical aortic and mitral valve prostheses
  • Patients with RF ablation of VT done in the last 12 months
  • Patients with known damaged ICD/CRT-D electrode or battery
  • Patients undergoing VT ablation who have not been implanted with ICD or CRT-D
  • Patients not willing or able to undergo clinical follow-up of ICD/CRT-D device
  • Patients with life expectancy < 1 year
  • Not able to understand or willing to sign informed consent
  • Age < 18 years Primary objective is a R wave sensing drop > 30% after VT substrate ablation procedure.

Specific (secondary) end-points:

  • incidence of VT recurrence after the ablation procedure;
  • risk factors for R wave sensing drop (> 30%) after the RF ablation of VT substrate;
  • time needed for R wave sensing recovery after the RF ablation procedure. Recruiting should not exceed 12 months with the minimal follow-up period of 12 months (24 months in total).

The risk categorisation of the study was done and the study was awarded a risk category A.

Sample size was chosen according to annual procedure volumes in Croatia and Switzerland. In addition, it is confirmed by power test (number needed to recruit: 52). Recruiting should not exceed 12 months. Categorical variables will be presented by contingency tables in absolute values and percentages. Categorical variables will be compared by the chi-square with Yates corrections or Fisher's exact test. Continuous data will be expressed as means and standard deviations or median with corresponding interquartile range. The differences in quantitative variables will be tested by Mann-Whitney U-test (non-parametric test for independent samples). Logistic regression will be used to analyse the association between all variables of interest and the R wave sensing drop. Multivariate logistic regression will be used to adjust for confounding factors. Predictors of the R wave sensing drop will be assessed in a univariate and multivariate Cox proportional hazards model. The statistical analysis will be done using SPSS Software Version 22.0 or newer (IBM SPSS Statistics, New York, USA).

This unique study offers the possibility to show the impact of RF ablation on short-term and long-term R wave sensing change assessed by ICD or CRT-D's ventricle electrode in patients with sustained VT and structural heart disease undergoing ablation procedure. This observational data is needed to further refine the treatment of these patients and to prevent possible ICD/CRT-D dysfunction which could endanger this patient population. Despite a high number of cohort registries for cardiovascular diseases (e.g. Danish heart registry, ORBIT-AF, GARFIELD AF registry, Swiss AF registry), there are scarce data on patients with structural VT and no data regarding R wave sensing changes influenced by RF energy application in ventricles. In addition, this could influence obligatory rhythm-monitoring duration and consequently hospitalization duration of patients with VT undergoing RF ablation procedures. Apart from the above mentioned, in those patients with non-optimal preprocedural R wave sensing, this could mean contraindication for procedure or having the need to do postprocedural defibrillation testing. It is likely, that data from our study will lead to future changes in periprocedural planning and modalities.

This study will be conducted in compliance with the current version of the Declaration of Helsinki, the ICH-GCP or ISO EN 14155 (as far as applicable) as well as all national legal and regulatory requirements. According to ethical regulations, the study plan with the proposed participant information and consent form as well as other project-specific documents will be submitted to Ethic committee of the participating centres.

Keywords
ventricular tachycardia, R wave; sensing, radiofrequency ablation, follow-up
Medical subject headings
Tachycardia, Ventricular

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. R wave sensing change

    R wave sensing drop > 30% after RF ablation of VT substrate in left and/or right ventricle assessed by ventricular electrode of the CIED

    Measured: immediately after the ablation procedure

Secondary outcomes (5)
  1. R wave sensing change 24h follow-up

    R wave sensing drop > 30% after RF ablation of VT substrate in left and/or right ventricle assessed by ventricular electrode of the CIED

    Measured: 24 hours after ablation procedure

  2. R wave sensing change 3-6 month follow-up

    R wave sensing drop > 30% after RF ablation of VT substrate in left and/or right ventricle assessed by ventricular electrode of the CIED

    Measured: 3-6 months after ablation procedure

  3. R wave sensing change 9-12 month follow-up

    R wave sensing drop > 30% after RF ablation of VT substrate in left and/or right ventricle assessed by ventricular electrode of the CIED

    Measured: 9-12 months after the ablation procedure

  4. Incidence of VT recurrence after the ablation procedure

    Assessing the VT recurrence after the ablation procedure by ICD or CRT-D interrogation adn function testing

    Measured: 12 months after the ablation procedure

  5. Risk factors for R wave sensing change after the RF ablation of VT substrate

    assessing risk factors for R wave sensing drop after the RF ablation of VT substrate

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Dec 2018
  2. Study startDec 2018 (estimated)
  3. Primary completionDec 2019 (estimated)
  4. Study completionDec 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
Target duration
12 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT03779165
Sponsor's protocol ID
ZAPSA01
Other IDs
UTN U1111-1223-2331
Acronym
RASA-VT
Status last verified
Dec 2018
First submitted
17 Dec 2018
Last updated
20 Dec 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Darrat YH, Agarwal A, Morales GX, Thompson J, Abdel-Latif A, Waespe K, DI Biase L, Natale A, Patwardan A, Elayi CS. Radiofrequency and Cryo-Ablation Effect on Transvenous Pacing and Defibrillatory Lead Integrity: An In Vitro Study. J Cardiovasc Electrophysiol. 2016 Aug;27(8):976-80. doi: 10.1111/jce.13007. Epub 2016 Jun 14.

    PubMed 27138905
  • Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ; Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace. 2015 Nov;17(11):1601-87. doi: 10.1093/europace/euv319. Epub 2015 Aug 29. No abstract available.

    PubMed 26318695

Questions about this trial

What is this clinical trial studying?

An observational study of Tachycardia, Ventricular and Catheter Ablation, run by University Hospital Sestre Milosrdnice at 4 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Croatia, Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ivan Zeljkovic, MD (0038513787733, ivanzeljkov@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

R wave sensing change (time frame: immediately after the ablation procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03779165, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2018.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in